FDA label cb6eeb40-550c-418c-9207-6199da3b310d

5 WARNINGS AND PRECAUTIONS Decreases in bone mineral density may occur. Consider bone mineral density monitoring. ( 5.1 ) Increases in total cholesterol may occur. Consider cholesterol monitoring. ( 5.2 ) Fatigue, dizziness and somnolence may occur. Exercise caution when operating machinery. ( 5.4 ) 5.1 Bone Effects Use of Letrozole tablet may cause decreases in bone mineral density (BMD). Consideration should be given to monitoring BMD. Results of a substudy to evaluate safety in the adjuvant setting comparing the effect on lumbar spine (L2-­L4) bone mineral density (BMD) of adjuvant treatment with letrozole to that with tamoxifen showed at 24 months a median decrease in lumbar spine BMD of 4.1% in the letrozole arm compared to a median increase of 0.3% in the tamoxifen arm (difference = 4.4%) ( P <0.0001) [see Adverse Reactions ( 6.1 )] . Updated results from the BMD substudy in the extended adjuvant setting demonstrated that at 2 years patients receiving letrozole had a median decrease from baseline of 3.8% in hip BMD compared to a median decrease of 2.0% in the placebo group. The changes from baseline in lumbar spine BMD in letrozole and placebo treated groups were not significantly different [see Adverse Reactions ( 6.2 )] . In the adjuvant trial the incidence of bone fractures at any time after randomization was 13.8% for letrozole and 10.5% for tamoxifen. The incidence of osteoporosis was 5.1% for letrozole and 2.7% for tamoxifen [see Adverse Reactions ( 6.1 )] . In the extended adjuvant trial the incidence of bone fractures at any time after randomization was 13.3% for letrozole and 7.8% for placebo. The incidence of new osteoporosis was 14.5% for letrozole and 7.8% for placebo [see Adverse Reactions ( 6.3 )] . 5.2 Cholesterol Consideration should be given to monitoring serum cholesterol. In the adjuvant trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients. CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients. Also in the adjuvant setting, an increase of ≥1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <= 1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%). Lipid lowering medications were required for 25% of patients on letrozole and 16% on tamoxifen [see Adverse Reactions ( 6.1 )] . 5.3 Hepatic Impairment Subjects with cirrhosis and severe hepatic impairment who were dosed with 2.5 mg of letrozole experienced approximately twice the exposure to letrozole as healthy volunteers with normal liver function. Therefore, a dose reduction is recommended for this patient population. The effect of hepatic impairment on letrozole exposure in cancer patients with elevated bilirubin levels has not been determined [see Dosage and Administration ( 2.5 )]. 5.4 Fatigue and Dizziness Because fatigue, dizziness, and somnolence have been reported with the use of Letrozole tablet, caution is advised when driving or using machinery until it is known how the patient reacts to letrozole use. 5.5 Laboratory Test Abnormalities No dose-related effect of letrozole on any hematologic or clinical chemistry parameter was evident. Moderate decreases in lymphocyte counts, of uncertain clinical significance, were observed in some patients receiving Letrozole tablets 2.5 mg. This depression was transient in about half of those affected. Two patients on Letrozole tablets developed thrombocytopenia; relationship to the study drug was unclear. Patient withdrawal due to laboratory abnormalities, whether related to study treatment or not, was infrequent.

6 ADVERSE REACTIONS The most serious adverse reactions from the use of letrozole tablets are: Bone effects [see Warnings and Precautions ( 5.1 )] Increases in cholesterol [see Warnings and Precautions ( 5.2 )] Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reactions (>20%) were hot flashes, arthralgia ( 6.1 ); flushing, asthenia, edema, arthralgia, headache, dizziness, hypercholesterolemia, sweating increased, bone pain ( 6.2 , 6.3 ); and musculoskeletal ( 6.4 ). To report SUSPECTED ADVERSE REACTIONS, contact QUALITEST PHARMACEUTICALS at 1-(800) 444-4011 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Adjuvant Treatment of Early Breast Cancer The median treatment duration of adjuvant treatment was 60 months and the median duration of follow-up for safety was 73 months for patients receiving letrozole tablets and tamoxifen. Certain adverse reactions were prospectively specified for analysis, based on the known pharmacologic properties and side effect profiles of the two drugs. Adverse reactions were analyzed irrespective of whether a symptom was present or absent at baseline. Most adverse reactions reported (approximately 75% of patients reporting 1 or more AE) were Grade 1 or Grade 2 applying the Common Toxicity Criteria Version 2.0/ Common Terminology Criteria for Adverse Events, version 3.0. Table 1 describes adverse reactions (Grades 1-4) irrespective of relationship to study treatment in the adjuvant trial for the monotherapy arms analysis (safety population). Table 1: Patients with Adverse Reactions (CTC Grades 1-4, Irrespective of Relationship to Study Drug) in the Adjuvant Study – Monotherapy Arms Analysis (Median Follow-up 73 Months; Median Treatment 60 Months) Grades 1-4 Grades 3-4 Adverse Reaction Letrozole N=2448 n (%) tamoxifen N=2447 n (%) Letrozole N=2448 n (%) tamoxifen N=2447 n (%) Pts with any adverse event 2310 (94.4) 2214 (90.5) 635 (25.9) 604 (24.7) Hypercholesterolemia 1280 (52.3) 700 (28.6) 11 (0.4) 6 (0.2) Hot Flashes/Flushes 821 (33.5) 929 (38.0) 0 - 0 - Arthralgia/Arthritis 618 (25.2) 501 (20.4) 85 (3.5) 50 (2.0) Night Sweats 357 (14.6) 426 (17.4) 0 - 0 - Bone Fractures 2 338 (13.8) 257 (10.5) - - - - Weight Increase 317 (12.9) 378 (15.4) 27 (1.1) 39 (1.6) Nausea 283 (11.6) 277 (11.3) 6 (0.2) 9 (0.4) Bone Fractures 1 247 (10.1) 174 (7.1) - - - - Fatigue (Lethargy, Malaise, Asthenia) 235 (9.6) 250 (10.2) 6 (0.2) 7 (0.3) Myalgia 217 (8.9) 212 (8.7) 18 (0.7) 14 (0.6) Edema 164 (6.7) 160 (6.5) 3 (0.1) 1 (<0.1) Weight Decrease 140 (5.7) 129 (5.3) 8 (0.3) 5 (0.2) Vaginal Bleeding 128 (5.2) 320 (13.1) 1 (<0.1) 8 (0.3) Back Pain 125 (5.1) 136 (5.6) 7 (0.3) 11 (0.4) Osteoporosis NOS 124 (5.1) 66 (2.7) 10 (0.4) 5 (0.2) Bone Pain 123 (5.0) 109 (4.5) 6 (0.2) 4 (0.2) Depression 119 (4.9) 114 (4.7) 16 (0.7) 14 (0.6) Vaginal Irritation 111 (4.5) 77 (3.1) 2 (<0.1) 2 (<0.1) Headache 105 (4.3) 94 (3.8) 9 (0.4) 5 (0.2) Pain in extremity 103 (4.2) 79 (3.2) 6 (0.2) 4 (0.2) Osteopenia 87 (3.6) 74 (3.0) 0 - 2 (<0.1) Dizziness/Light-Headedness 84 (3.4) 84 (3.4) 1 (<0.1) 6 (0.2) Alopecia 83 (3.4) 84 (3.4) 0 - 0 - Vomiting 80 (3.3) 80 (3.3) 3 (0.1) 5 (0.2) Cataract 49 (2.0) 54 (2.2) 16 (0.7) 17 (0.7) Constipation 49 (2.0) 71 (2.9) 3 (0.1) 1 (<0.1) Breast Pain 37 (1.5) 43 (1.8) 1 (<0.1) 0 - Anorexia 20 (0.8) 20 (0.8) 1 (<0.1) 1 (<0.1) Endometrial Hyperplasia/Cancer 2,3 11/1909 (0.6) 70/1943 (3.6) - - - - Endometrial Proliferation Disorders 10 (0.3) 71 (1.8) 0 - 14 (0.6) Endometrial Hyperplasia/Cancer 1,3 6/1909 (0.3) 57/1943 (2.9) - - - - Other Endometrial Disorders 2 (<0.1) 3 (0.1) 0 - 0 - Myocardial Infarction 1 24 (1.0) 12 (0.5) - - - - Myocardial Infarction 2 37 (1.5) 25 (1.0) - - - - Myocardial Ischemia 6 (0.2) 9 (0.4) - - - - Cerebrovascular Accident 1 52 (2.1) 46 (1.9) - - - - Cerebrovascular Accident 2 70 (2.9) 63 (2.6) - - - - Angina 1 26 (1.1) 24 (1.0) - - - - Angina 2 32 (1.3) 31 (1.3) - - - - Thromboembolic Event 1 51 (2.1) 89 (3.6) - - - Thromboembolic Event 2 71 (2.9) 111 (4.5) - - - - Other Cardiovascular 1 260 (10.6) 256 (10.5) - - - - Other Cardiovascular 2 312 (12.7) 337 (13.8) - - - - Second Malignancies 1 53 (2.2) 78 (3.2) - - - - Second Malignancies 2 102 (4.2) 119 (4.9) - - - - 1 During study treatment, based on Safety Monotherapy population 2 Any time after randomization, including post treatment follow-up 3 Excluding women who had undergone hysterectomy before study entry Note: Cardiovascular (including cerebrovascular and thromboembolic), skeletal and urogenital/endometrial events and second malignancies were collected life-long. All of these events were assumed to be of CTC grade 3-5 and were not individually graded. When considering all grades during study treatment, a higher incidence of events was seen for letrozole tablets regarding fractures (10.1% vs 7.1%), myocardial infarctions (1.0% vs 0.5%), and arthralgia (25.2% vs 20.4%) (letrozole tablets vs tamoxifen respectively). A higher incidence was seen for tamoxifen regarding thromboembolic events (2.1% vs 3.6%), endometrial hyperplasia/cancer (0.3% vs 2.9%), and endometrial proliferation disorders (0.3% vs 1.8%) (letrozole tablets vs tamoxifen respectively). At a median follow up of 73 months, a higher incidence of events was seen for letrozole tablets (13.8%) than for tamoxifen (10.5%) regarding fractures. A higher incidence was seen for tamoxifen compared to letrozole tablets regarding thromboembolic events (4.5% vs 2.9%), and endometrial hyperplasia or cancer (2.9% vs 0.4%) (tamoxifen vs letrozole tablets, respectively). Bone Study: Results of a phase 3 safety trial in 262 postmenopausal women with resected receptor positive early breast cancer in the adjuvant setting comparing the effect on lumbar spine (L2-L4) bone mineral density (BMD) of adjuvant treatment with letrozole to that with tamoxifen showed at 24 months a median decrease in lumbar spine BMD of 4.1% in the letrozole arm compared to a median increase of 0.3% in the tamoxifen arm (difference = 4.4%) ( P <0.0001). No patients with a normal BMD at baseline became osteoporotic over the 2 years and only 1 patient with osteopenia at baseline (T score of -1.9) developed osteoporosis during the treatment period (assessment by central review). The results for total hip BMD were similar, although the differences between the two treatments were less pronounced. During the 2 year period, fractures were reported by 4 of 103 patients (4%) in the letrozole arm, and 6 of 97 patients (6%) in the tamoxifen arm. Lipid Study: In a phase 3 safety trial in 262 postmenopausal women with resected receptor positive early breast cancer at 24 months comparing the effects on lipid profiles of adjuvant letrozole to tamoxifen, 12% of patients on letrozole had at least one total cholesterol value of a higher CTCAE grade than at baseline compared with 4% of patients on tamoxifen. 6.2 Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 24 Months The median duration of extended adjuvant treatment was 24 months and the median duration of follow-up for safety was 28 months for patients receiving letrozole tablets and placebo. Table 2 describes the adverse reactions occurring at a frequency of at least 5% in any treatment group during treatment. Most adverse reactions reported were Grade 1 and Grade 2 based on the Common Toxicity Criteria Version 2.0. In the extended adjuvant setting, the reported drug-related adverse reactions that were significantly different from placebo were hot flashes, arthralgia/arthritis, and myalgia. Table 2: Percentage of Patients with Adverse Reactions Number (%) of Patients with Grade 1-4 Adverse Reaction Number (%) of Patients with Grade 3-4 Adverse Reaction Letrozole N=2563 Placebo N=2573 Letrozole N=2563 Placebo N=2573 Any Adverse Reaction 2232 (87.1) 2174 (84.5) 419 (16.3) 389 (15.1) Vascular Disorders 1375 (53.6) 1230 (47.8) 59 (2.3) 74 (2.9) Flushing 1273 (49.7) 1114 (43.3) 3 (0.1) 0 - General Disorders 1154 (45) 1090 (42.4) 30 (1.2) 28 (1.1) Asthenia 862 (33.6) 826 (32.1) 16 (0.6) 7 (0.3) Edema NOS 471 (18.4) 416 (16.2) 4 (0.2) 3 (0.1) Musculoskeletal Disorders 978 (38.2) 836 (32.5) 71 (2.8) 50 (1.9) Arthralgia 565 (22) 465 (18.1) 25 (1) 20 (0.8) Arthritis NOS 173 (6.7) 124 (4.8) 10 (0.4) 5 (0.2) Myalgia 171 (6.7) 122 (4.7) 8 (0.3) 6 (0.2) Back Pain 129 (5) 112 (4.4) 8 (0.3) 7 (0.3) Nervous System Disorders 863 (33.7) 819 (31.8) 65 (2.5) 58 (2.3) Headache 516 (20.1) 508 (19.7) 18 (0.7) 17 (0.7) Dizziness 363 (14.2) 342 (13.3) 9 (0.4) 6 (0.2) Skin Disorders 830 (32.4) 787 (30.6) 17 (0.7) 16 (0.6) Sweating Increased 619 (24.2) 577 (22.4) 1 (<0.1) 0 - Gastrointestinal Disorders 725 (28.3) 731 (28.4) 43 (1.7) 42 (1.6) Constipation 290 (11.3) 304 (11.8) 6 (0.2) 2 (<0.1) Nausea 221 (8.6) 212 (8.2) 3 (0.1) 10 (0.4) Diarrhea NOS 128 (5) 143 (5.6) 12 (0.5) 8 (0.3) Metabolic Disorders 551 (21.5) 537 (20.9) 24 (0.9) 32 (1.2) Hypercholesterolemia 401 (15.6) 398 (15.5) 2 (<0.1) 5 (0.2) Reproductive Disorders 303 (11.8) 357 (13.9) 9 (0.4) 8 (0.3) Vaginal Hemorrhage 123 (4.8) 171 (6.6) 2 (<0.1) 5 (0.2) Vulvovaginal Dryness 137 (5.3) 127 (4.9) 0 - 0 - Psychiatric Disorders 320 (12.5) 276 (10.7) 21 (0.8) 16 (0.6) Insomnia 149 (5.8) 120 (4.7) 2 (<0.1) 2 (<0.1) Respiratory Disorders 279 (10.9) 260 (10.1) 30 (1.2) 28 (1.1) Dyspnea 140 (5.5) 137 (5.3) 21 (0.8) 18 (0.7) Investigations 184 (7.2) 147 (5.7) 13 (0.5) 13 (0.5) Infections and Infestations 166 (6.5) 163 (6.3) 40 (1.6) 33 (1.3) Renal Disorders 130 (5.1) 100 (3.9) 12 (0.5) 6 (0.2) Based on a median follow-up of patients for 28 months, the incidence of clinical fractures from the core randomized study in patients who received letrozole tablets was 5.9% (152) and placebo was 5.5% (142). The incidence of self-reported osteoporosis was higher in patients who received letrozole tablets 6.9% (176) than in patients who received placebo 5.5% (141). Bisphosphonates were administered to 21.1% of the patients who received letrozole tablets and 18.7% of the patients who received placebo. The incidence of cardiovascular ischemic events from the core randomized study was comparable between patients who received letrozole tablets 6.8% (175) and placebo 6.5% (167). A patient-reported measure that captures treatment impact on important symptoms associated with estrogen deficiency demonstrated a difference in favor of placebo for vasomotor and sexual symptom domains. Bone Sub-study: [see Warnings and Precautions ( 5.1 )] . Lipid Sub-study: In the extended adjuvant setting, based on a median duration of follow-up of 62 months, there was no significant difference between letrozole tablets and placebo in total cholesterol or in any lipid fraction at any time over 5 years. Use of lipid lowering drugs or dietary management of elevated lipids was allowed [see Warnings and Precautions ( 5.2 )] . 6.3 Updated Analysis, Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 60 Months The extended adjuvant treatment trial was unblinded early [see Adverse Reactions ( 6.2 )] . At the updated (final analysis), overall the side effects seen were consistent to those seen at a median treatment duration of 24 months. During treatment or within 30 days of stopping treatment (median duration of treatment 60 months) a higher rate of fractures was observed for letrozole tablets (10.4%) compared to placebo (5.8%), as also a higher rate of osteoporosis (letrozole tablets 12.2% vs placebo 6.4%). Based on 62 months median duration of follow-up in the randomized letrozole arm in the Safety population the incidence of new fractures at any time after randomization was 13.3% for letrozole and 7.8% for placebo. The incidence of new osteoporosis was 14.5% for letrozole and 7.8% for placebo. During treatment or within 30 days of stopping treatment (median duration of treatment 60 months) the incidence of cardiovascular events was 9.8% for letrozole tablets and 7.0% for placebo. Based on 62 months median duration of follow-up in the randomized letrozole arm in the Safety population the incidence of cardiovascular disease at any time after randomization was 14.4% for letrozole and 9.8% for placebo. Lipid sub-study: In the extended adjuvant setting, based on a median duration of follow-up of 62 months, there was no significant difference between letrozole and placebo in total cholesterol or in any lipid fraction over 5 years. Use of lipid lowering drugs or dietary management of elevated lipids was allowed. [see Warnings and Precautions( 5.2 )] 6.4 First-Line Treatment of Advanced Breast Cancer A total of 455 patients were treated for a median time of exposure of 11 months. The incidence of adverse reactions was similar for letrozole and tamoxifen. The most frequently reported adverse reactions were bone pain, hot flushes, back pain, nausea, arthralgia and dyspnea. Discontinuations for adverse reactions other than progression of tumor occurred in 10/455 (2%) of patients on letrozole tablets and in 15/455 (3%) of patients on tamoxifen. Adverse reactions, regardless of relationship to study drug, that were reported in at least 5% of the patients treated with letrozole tablets 2.5 mg or tamoxifen 20 mg in the first-line treatment study are shown in Table 3. Table 3: Percentage (%) of Patients with Adverse Reactions Adverse Reaction Letrozole 2.5 mg (N=455) % tamoxifen 20 mg (N=455) % General Disorders Fatigue 13 13 Chest Pain 8 9 Edema Peripheral 5 6 Pain NOS 5 7 Weakness 6 4 Investigations Weight Decreased 7 5 Vascular Disorders Hot Flushes 19 16 Hypertension 8 4 Gastrointestinal Disorders Nausea 17 17 Constipation 10 11 Diarrhea 8 4 Vomiting 7 8 Infections/Infestations Influenza 6 4 Urinary Tract Infection NOS 6 3 Injury, Poisoning and Procedural Complications Post-Mastectomy Lymphedema 7 7 Metabolism and Nutrition Disorders Anorexia 4 6 Musculoskeletal and Connective Tissue Disorders Bone Pain 22 21 Back Pain 18 19 Arthralgia 16 15 Pain in Limb 10 8 Nervous System Disorders Headache NOS 8 7 Psychiatric Disorders Insomnia 7 4 Reproductive System and Breast Disorders Breast Pain 7 7 Respiratory, Thoracic and Mediastinal Disorders Dyspnea 18 17 Cough 13 13 Chest Wall Pain 6 6 Other less frequent (≤2%) adverse reactions considered consequential for both treatment groups, included peripheral thromboembolic events, cardiovascular events, and cerebrovascular events. Peripheral thromboembolic events included venous thrombosis, thrombophlebitis, portal vein thrombosis and pulmonary embolism. Cardiovascular events included angina, myocardial infarction, myocardial ischemia, and coronary heart disease. Cerebrovascular events included transient ischemic attacks, thrombotic or hemorrhagic strokes and development of hemiparesis. 6.5 Second-Line Treatment of Advanced Breast Cancer Study discontinuations in the megestrol acetate comparison study for adverse reactions other than progression of tumor were 5/188 (2.7%) on letrozole 0.5 mg, in 4/174 (2.3%) on letrozole 2.5 mg, and in 15/190 (7.9%) on megestrol acetate. There were fewer thromboembolic events at both letrozole doses than on the megestrol acetate arm (0.6% vs 4.7%). There was also less vaginal bleeding (0.3% vs 3.2%) on letrozole than on megestrol acetate. In the aminoglutethimide comparison study, discontinuations for reasons other than progression occurred in 6/193 (3.1%) on 0.5 mg letrozole, 7/185 (3.8%) on 2.5 mg letrozole, and 7/178 (3.9%) of patients on aminoglutethimide. Comparisons of the incidence of adverse reactions revealed no significant differences between the high and low dose letrozole groups in either study. Most of the adverse reactions observed in all treatment groups were mild to moderate in severity and it was generally not possible to distinguish adverse reactions due to treatment from the consequences of the patient’s metastatic breast cancer, the effects of estrogen deprivation, or intercurrent illness. Adverse reactions, regardless of relationship to study drug, that were reported in at least 5% of the patients treated with letrozole 0.5 mg, letrozole 2.5 mg, megestrol acetate, or aminoglutethimide in the two controlled trials are shown in Table 4. Table 4: Percentage (%) of Patients with Adverse Reactions 1 Includes peripheral edema, leg edema, dependent edema, edema 2 Includes musculoskeletal pain, skeletal pain, back pain, arm pain, leg pain 3 Includes rash, erythematous rash, maculopapular rash, psoriasiform rash, vesicular rash Adverse Reaction Pooled Letrozole 2.5 mg (N=359) % Pooled Letrozole 0.5 mg (N=380) % megestrol acetate 160 mg (N=189) % aminoglutethimide 500 mg (N=178) % Body as a Whole Fatigue 8 6 11 3 Chest Pain 6 3 7 3 Peripheral Edema 1 5 5 8 3 Asthenia 4 5 4 5 Weight Increase 2 2 9 3 Cardiovascular Hypertension 5 7 5 6 Digestive System Nausea 13 15 9 14 Vomiting 7 7 5 9 Constipation 6 7 9 7 Diarrhea 6 5 3 4 Pain-Abdominal 6 5 9 8 Anorexia 5 3 5 5 Dyspepsia 3 4 6 5 Infections/Infestations Viral Infection 6 5 6 3 Lab Abnormality Hypercholesterolemia 3 3 0 6 Musculoskeletal System Musculoskeletal 2 21 22 30 14 Arthralgia 8 8 8 3 Nervous System Headache 9 12 9 7 Somnolence 3 2 2 9 Dizziness 3 5 7 3 Respiratory System Dyspnea 7 9 16 5 Coughing 6 5 7 5 Skin and Appendages Hot Flushes 6 5 4 3 Rash 3 5 4 3 12 Pruritus 1 2 5 3 Other less frequent (<5%) adverse reactions considered consequential and reported in at least 3 patients treated with letrozole tablets, included hypercalcemia, fracture, depression, anxiety, pleural effusion, alopecia, increased sweating and vertigo. 6.6 First and Second-Line Treatment of Advanced Breast Cancer In the combined analysis of the first- and second-line metastatic trials and post-marketing experiences other adverse reactions that were reported were cataract, eye irritation, palpitations, cardiac failure, tachycardia, dysesthesia (including hypesthesia/paresthesia), arterial thrombosis, memory impairment, irritability, nervousness, urticaria, increased urinary frequency, leukopenia, stomatitis cancer pain, pyrexia, vaginal discharge, appetite increase, dryness of skin and mucosa (including dry mouth), and disturbances of taste and thirst. 6.7 Postmarketing Experience Cases of blurred vision, increased hepatic enzymes, angioedema, anaphylactic reactions, toxic epidermal necrolysis, erythema multiforme, and hepatitis have been reported. Cases of carpal tunnel syndrome and trigger finger have been identified during post approval use of Letrozole.

<table width="612px" cellpadding="1"> <caption>Table 1: Patients with Adverse Reactions (CTC Grades 1-4, Irrespective of Relationship to Study Drug) in the Adjuvant Study &#x2013; Monotherapy Arms Analysis (Median Follow-up 73 Months; Median Treatment 60 Months)</caption> <col/> <col/> <col/> <col/> <col/> <tbody> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> </td> <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Grades 1-4</content> </td> <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Grades 3-4</content> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Adverse Reaction</content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph> <content styleCode="bold">Letrozole N=2448 </content> <content styleCode="bold">n (%) </content> </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph> <content styleCode="bold">tamoxifen N=2447 </content> <content styleCode="bold">n (%) </content> </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph> <content styleCode="bold">Letrozole N=2448 </content> <content styleCode="bold">n (%)</content> </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph> <content styleCode="bold">tamoxifen N=2447 </content> <content styleCode="bold">n (%) </content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Pts with any adverse event</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">2310 (94.4)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">2214 (90.5)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">635 (25.9)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">604 (24.7)</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Hypercholesterolemia</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">1280 (52.3)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">700 (28.6)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">11 (0.4)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">6 (0.2)</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Hot Flashes/Flushes</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">821 (33.5)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">929 (38.0)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">0 -</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">0 -</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Arthralgia/Arthritis</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">618 (25.2)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">501 (20.4)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">85 (3.5)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">50 (2.0)</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Night Sweats</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">357 (14.6)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">426 (17.4)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">0 -</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">0 -</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Bone Fractures² </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>338 (13.8)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>257 (10.5)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>- -</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>- -</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Weight Increase</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>317 (12.9)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">378 (15.4)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">27 (1.1)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">39 (1.6)</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Nausea</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">283 (11.6)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>277 (11.3)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>6 (0.2)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>9 (0.4)</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Bone Fractures¹ </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">247 (10.1)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>174 (7.1)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>- -</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>- -</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Fatigue (Lethargy, Malaise, Asthenia)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">235 (9.6)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">250 (10.2)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>6 (0.2)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>7 (0.3)</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Myalgia</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">217 (8.9)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">212 (8.7)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">18 (0.7)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>14 (0.6)</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Edema</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">164 (6.7)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">160 (6.5)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">3 (0.1)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>1 (&lt;0.1)</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Weight Decrease</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">140 (5.7)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">129 (5.3)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>8 (0.3)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>5 (0.2)</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Vaginal Bleeding</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">128 (5.2)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>320 (13.1)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>1 (&lt;0.1)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">8 (0.3)</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Back Pain</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">125 (5.1)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">136 (5.6)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">7 (0.3)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>11 (0.4)</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Osteoporosis NOS</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>124 (5.1)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">66 (2.7)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">10 (0.4)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>5 (0.2)</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Bone Pain</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>123 (5.0)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">109 (4.5)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">6 (0.2)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>4 (0.2)</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Depression</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>119 (4.9)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 114 (4.7)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 16 (0.7)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 14 (0.6)</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Vaginal Irritation</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 111 (4.5)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 77 (3.1)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 2 (&lt;0.1)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>2 (&lt;0.1)</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Headache</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>105 (4.3) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 94 (3.8)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>9 (0.4) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 5 (0.2)</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Pain in extremity</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>103 (4.2)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 79 (3.2)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>6 (0.2) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 4 (0.2)</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Osteopenia</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 87 (3.6)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>74 (3.0) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>0 - </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>2 (&lt;0.1) </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Dizziness/Light-Headedness</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 84 (3.4)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 84 (3.4)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 1 (&lt;0.1)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>6 (0.2) </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Alopecia</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 83 (3.4)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>84 (3.4) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>0 - </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>0 - </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Vomiting</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 80 (3.3)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>80 (3.3)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 3 (0.1)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 5 (0.2)</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Cataract</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">49 (2.0)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>54 (2.2) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>16 (0.7)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>17 (0.7)</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Constipation</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>49 (2.0) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>71 (2.9)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>3 (0.1)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>1 (&lt;0.1)</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Breast Pain</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>37 (1.5) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 43 (1.8)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>1 (&lt;0.1) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>0 - </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Anorexia</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>20 (0.8) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 20 (0.8)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 1 (&lt;0.1)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>1 (&lt;0.1) </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Endometrial Hyperplasia/Cancer ^2,3 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>11/1909 (0.6) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>70/1943 (3.6)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- -</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>- -</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Endometrial Proliferation Disorders</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>10 (0.3) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 71 (1.8)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>0 -</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>14 (0.6) </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Endometrial Hyperplasia/Cancer^1,3 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 6/1909 (0.3)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>57/1943 (2.9) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- -</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- -</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Other Endometrial Disorders</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 2 (&lt;0.1)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 3 (0.1)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>0 -</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>0 -</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Myocardial Infarction¹ </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>24 (1.0) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>12 (0.5) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- -</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- -</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Myocardial Infarction² </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>37 (1.5) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>25 (1.0) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- -</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- -</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Myocardial Ischemia</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 6 (0.2)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>9 (0.4)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- -</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Cerebrovascular Accident¹ </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 52 (2.1)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>46 (1.9)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Cerebrovascular Accident² </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>70 (2.9) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 63 (2.6)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Angina¹ </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 26 (1.1)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 24 (1.0)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Angina² </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>32 (1.3) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>31 (1.3) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Thromboembolic Event¹ </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>51 (2.1) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 89 (3.6)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> - </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Thromboembolic Event² </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>71 (2.9)</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 111 (4.5)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> - -</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> - -</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Other Cardiovascular¹ </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 260 (10.6)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 256 (10.5)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> - -</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Other Cardiovascular² </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 312 (12.7)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 337 (13.8)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Second Malignancies¹ </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 53 (2.2)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 78 (3.2)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule ">Second Malignancies² </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>102 (4.2) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph>119 (4.9) </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule ">- - </td> </tr> <tr> <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule "> <paragraph> ¹ During study treatment, based on Safety Monotherapy population</paragraph> <paragraph> ² Any time after randomization, including post treatment follow-up</paragraph> <paragraph> ³ Excluding women who had undergone hysterectomy before study entry</paragraph> <paragraph>Note: Cardiovascular (including cerebrovascular and thromboembolic), skeletal and urogenital/endometrial events and second malignancies were collected life-long. All of these events were assumed to be of CTC grade 3-5 and were not individually graded.</paragraph> </td> </tr> </tbody> </table>

<table width="552px"> <caption>Table 2: Percentage of Patients with Adverse Reactions </caption> <col/> <col/> <col/> <col/> <col/> <tbody> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> </td> <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Number (%) of Patients with Grade 1-4 Adverse Reaction </content> </td> <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Number (%) of Patients with Grade 3-4 Adverse Reaction </content> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Letrozole N=2563 </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Placebo N=2573 </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Letrozole N=2563</content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Placebo N=2573 </content> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Any Adverse Reaction </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 2232 (87.1)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 2174 (84.5)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 419 (16.3) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 389 (15.1) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Vascular Disorders </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 1375 (53.6) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 1230 (47.8) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 59 (2.3) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 74 (2.9) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Flushing </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 1273 (49.7)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 1114 (43.3) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 3 (0.1) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 0 -</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">General Disorders </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 1154 (45)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 1090 (42.4) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 30 (1.2) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 28 (1.1) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Asthenia </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 862 (33.6) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 826 (32.1) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 16 (0.6) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 7 (0.3) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Edema NOS </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 471 (18.4) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 416 (16.2) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 4 (0.2) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 3 (0.1) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Musculoskeletal Disorders </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 978 (38.2) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 836 (32.5) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 71 (2.8) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 50 (1.9) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Arthralgia</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 565 (22) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 465 (18.1) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 25 (1) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 20 (0.8)</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Arthritis NOS </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 173 (6.7)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 124 (4.8) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 10 (0.4) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 5 (0.2) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Myalgia </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 171 (6.7) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 122 (4.7) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 8 (0.3) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 6 (0.2) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Back Pain </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 129 (5) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 112 (4.4) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 8 (0.3) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 7 (0.3) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Nervous System Disorders </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 863 (33.7) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 819 (31.8) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 65 (2.5) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 58 (2.3) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Headache</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 516 (20.1)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 508 (19.7) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 18 (0.7) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 17 (0.7) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Dizziness </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 363 (14.2) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 342 (13.3) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 9 (0.4) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 6 (0.2) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Skin Disorders </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 830 (32.4) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 787 (30.6)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 17 (0.7) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 16 (0.6) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Sweating Increased </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 619 (24.2)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 577 (22.4) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 1 (&lt;0.1) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 0 -</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Gastrointestinal Disorders</content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 725 (28.3)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 731 (28.4) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 43 (1.7) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 42 (1.6) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Constipation </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 290 (11.3)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 304 (11.8) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 6 (0.2) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 2 (&lt;0.1) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Nausea </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 221 (8.6) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 212 (8.2) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 3 (0.1) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 10 (0.4) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Diarrhea NOS </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 128 (5) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 143 (5.6) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 12 (0.5) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 8 (0.3) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Metabolic Disorders </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 551 (21.5) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 537 (20.9)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 24 (0.9) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 32 (1.2) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Hypercholesterolemia </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 401 (15.6) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 398 (15.5)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 2 (&lt;0.1) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 5 (0.2) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Reproductive Disorders </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 303 (11.8) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 357 (13.9) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 9 (0.4) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 8 (0.3) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Vaginal Hemorrhage </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 123 (4.8)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 171 (6.6) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 2 (&lt;0.1) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 5 (0.2) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Vulvovaginal Dryness </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 137 (5.3) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 127 (4.9) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 0 -</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 0 -</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Psychiatric Disorders </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 320 (12.5) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 276 (10.7) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 21 (0.8) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 16 (0.6) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Insomnia </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 149 (5.8) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 120 (4.7) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 2 (&lt;0.1) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 2 (&lt;0.1) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Respiratory Disorders </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 279 (10.9) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 260 (10.1) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 30 (1.2) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 28 (1.1) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> Dyspnea </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 140 (5.5) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 137 (5.3) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 21 (0.8) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 18 (0.7) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Investigations </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 184 (7.2) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 147 (5.7)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 13 (0.5) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 13 (0.5) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Infections and Infestations </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 166 (6.5) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 163 (6.3)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 40 (1.6) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 33 (1.3) </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Renal Disorders </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 130 (5.1) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 100 (3.9) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 12 (0.5) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule "> 6 (0.2) </td> </tr> </tbody> </table>

<table width="576px"> <caption>Table 3: Percentage (%) of Patients with Adverse Reactions </caption> <col width="1px"/> <col width="1px"/> <col width="1px"/> <tbody> <tr> <th styleCode=" Toprule Lrule Rrule "> Adverse Reaction </th> <th align="center" styleCode=" Toprule Lrule Rrule "> Letrozole 2.5 mg (N=455) %</th> <th align="center" styleCode=" Toprule Lrule Rrule "> tamoxifen 20 mg (N=455) %</th> </tr> <tr> <td styleCode=" Toprule Lrule Rrule "> <content styleCode="bold">General Disorders </content> </td> <td align="center" styleCode=" Toprule Rrule "> </td> <td align="center" styleCode=" Toprule Rrule "> </td> </tr> <tr> <td styleCode=" Lrule Rrule "> Fatigue </td> <td align="center" styleCode=" Rrule "> 13</td> <td align="center" styleCode=" Rrule "> 13</td> </tr> <tr> <td styleCode=" Lrule Rrule "> Chest Pain</td> <td align="center" styleCode=" Rrule "> 8</td> <td align="center" styleCode=" Rrule "> 9</td> </tr> <tr> <td styleCode=" Lrule Rrule "> Edema Peripheral </td> <td align="center" styleCode=" Rrule "> 5</td> <td align="center" styleCode=" Rrule "> 6</td> </tr> <tr> <td styleCode=" Lrule Rrule "> Pain NOS </td> <td align="center" styleCode=" Rrule "> 5</td> <td align="center" styleCode=" Rrule "> 7</td> </tr> <tr> <td styleCode=" Lrule Rrule "> Weakness </td> <td align="center" styleCode=" Rrule "> 6</td> <td align="center" styleCode=" Rrule "> 4</td> </tr> <tr> <td styleCode=" Toprule Lrule Rrule "> <content styleCode="bold">Investigations </content> </td> <td align="center" styleCode=" Toprule Rrule "> </td> <td align="center" styleCode=" Toprule Rrule "> </td> </tr> <tr> <td styleCode=" Lrule Rrule "> Weight Decreased</td> <td align="center" styleCode=" Rrule "> 7</td> <td align="center" styleCode=" Rrule "> 5</td> </tr> <tr> <td styleCode=" Toprule Lrule Rrule "> <content styleCode="bold">Vascular Disorders</content> </td> <td align="center" styleCode=" Toprule Rrule "> </td> <td align="center" styleCode=" Toprule Rrule "> </td> </tr> <tr> <td styleCode=" Lrule Rrule "> Hot Flushes </td> <td align="center" styleCode=" Rrule "> 19</td> <td align="center" styleCode=" Rrule "> 16</td> </tr> <tr> <td styleCode=" Lrule Rrule "> Hypertension </td> <td align="center" styleCode=" Rrule "> 8</td> <td align="center" styleCode=" Rrule "> 4</td> </tr> <tr> <td styleCode=" Toprule Lrule Rrule "> <content styleCode="bold">Gastrointestinal Disorders </content> </td> <td align="center" styleCode=" Toprule Rrule "> </td> <td align="center" styleCode=" Toprule Rrule "> </td> </tr> <tr> <td styleCode=" Lrule Rrule "> Nausea</td> <td align="center" styleCode=" Rrule "> 17</td> <td align="center" styleCode=" Rrule "> 17</td> </tr> <tr> <td styleCode=" Lrule Rrule "> Constipation </td> <td align="center" styleCode=" Rrule "> 10</td> <td align="center" styleCode=" Rrule "> 11</td> </tr> <tr> <td styleCode=" Lrule Rrule "> Diarrhea</td> <td align="center" styleCode=" Rrule "> 8</td> <td align="center" styleCode=" Rrule "> 4</td> </tr> <tr> <td styleCode=" Lrule Rrule "> Vomiting</td> <td align="center" styleCode=" Rrule "> 7</td> <td align="center" styleCode=" Rrule "> 8</td> </tr> <tr> <td styleCode=" Toprule Lrule Rrule "> <content styleCode="bold">Infections/Infestations</content> </td> <td align="center" styleCode=" Toprule Rrule "> </td> <td align="center" styleCode=" Toprule Rrule "> </td> </tr> <tr> <td styleCode=" Lrule Rrule "> Influenza</td> <td align="center" styleCode=" Rrule "> 6</td> <td align="center" styleCode=" Rrule "> 4</td> </tr> <tr> <td styleCode=" Lrule Rrule "> Urinary Tract Infection NOS</td> <td align="center" styleCode=" Rrule "> 6</td> <td align="center" styleCode=" Rrule "> 3</td> </tr> <tr> <td styleCode=" Toprule Lrule Rrule "> <content styleCode="bold">Injury, Poisoning and Procedural Complications </content> </td> <td align="center" styleCode=" Toprule Rrule "> </td> <td align="center" styleCode=" Toprule Rrule "> </td> </tr> <tr> <td styleCode=" Lrule Rrule "> Post-Mastectomy Lymphedema</td> <td align="center" styleCode=" Rrule "> 7</td> <td align="center" styleCode=" Rrule "> 7</td> </tr> <tr> <td styleCode=" Toprule Lrule Rrule "> <content styleCode="bold">Metabolism and Nutrition Disorders</content> </td> <td align="center" styleCode=" Toprule Rrule "> </td> <td align="center" styleCode=" Toprule Rrule "> </td> </tr> <tr> <td styleCode=" Lrule Rrule "> Anorexia</td> <td align="center" styleCode=" Rrule "> 4</td> <td align="center" styleCode=" Rrule "> 6</td> </tr> <tr> <td styleCode=" Toprule Lrule Rrule "> <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders</content> </td> <td align="center" styleCode=" Toprule Rrule "> </td> <td align="center" styleCode=" Toprule Rrule "> </td> </tr> <tr> <td styleCode=" Lrule Rrule "> Bone Pain</td> <td align="center" styleCode=" Rrule "> 22</td> <td align="center" styleCode=" Rrule "> 21</td> </tr> <tr> <td styleCode=" Lrule Rrule "> Back Pain</td> <td align="center" styleCode=" Rrule "> 18</td> <td align="center" styleCode=" Rrule "> 19</td> </tr> <tr> <td styleCode=" Lrule Rrule "> Arthralgia</td> <td align="center" styleCode=" Rrule "> 16</td> <td align="center" styleCode=" Rrule "> 15</td> </tr> <tr> <td styleCode=" Lrule Rrule "> Pain in Limb</td> <td align="center" styleCode=" Rrule "> 10 </td> <td align="center" styleCode=" Rrule "> 8</td> </tr> <tr> <td styleCode=" Toprule Lrule Rrule "> <content styleCode="bold">Nervous System Disorders</content> </td> <td align="center" styleCode=" Toprule Rrule "> </td> <td align="center" styleCode=" Toprule Rrule "> </td> </tr> <tr> <td styleCode=" Lrule Rrule "> Headache NOS</td> <td align="center" styleCode=" Rrule "> 8</td> <td align="center" styleCode=" Rrule "> 7</td> </tr> <tr> <td styleCode=" Toprule Lrule Rrule "> <content styleCode="bold">Psychiatric Disorders</content> </td> <td align="center" styleCode=" Toprule Rrule "> </td> <td align="center" styleCode=" Toprule Rrule "> </td> </tr> <tr> <td styleCode=" Lrule Rrule "> Insomnia</td> <td align="center" styleCode=" Rrule "> 7</td> <td align="center" styleCode=" Rrule "> 4</td> </tr> <tr> <td styleCode=" Toprule Lrule Rrule "> <content styleCode="bold">Reproductive System and Breast Disorders</content> </td> <td align="center" styleCode=" Toprule Rrule "> </td> <td align="center" styleCode=" Toprule Rrule "> </td> </tr> <tr> <td styleCode=" Lrule Rrule "> Breast Pain</td> <td align="center" styleCode=" Rrule "> 7</td> <td align="center" styleCode=" Rrule "> 7</td> </tr> <tr> <td styleCode=" Toprule Lrule Rrule "> <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content> </td> <td align="center" styleCode=" Toprule Rrule "> </td> <td align="center" styleCode=" Toprule Rrule "> </td> </tr> <tr> <td styleCode=" Lrule Rrule "> Dyspnea</td> <td align="center" styleCode=" Rrule "> 18</td> <td align="center" styleCode=" Rrule "> 17</td> </tr> <tr> <td styleCode=" Lrule Rrule "> Cough</td> <td align="center" styleCode=" Rrule "> 13</td> <td align="center" styleCode=" Rrule "> 13</td> </tr> <tr> <td styleCode=" Botrule Lrule Rrule "> Chest Wall Pain</td> <td align="center" styleCode=" Botrule Rrule "> 6</td> <td align="center" styleCode=" Botrule Rrule "> 6</td> </tr> </tbody> </table>